Loading...
Symbols:
Get Seeking Alpha Free Stock Alerts by Email!
Get Free Stock Alerts by Email!
Transcripts
- Alnylam Pharmaceuticals, Inc. Q3 2008 Earnings Call Transcript
- eHealth, Inc. Q3 2008 Earnings Call Transcript
- MIPS Technologies, Inc. F1Q09 (Qtr End 09/30/08) Earnings Call Transcript
- Alexza Pharmaceuticals, Inc. Q3 2008 Earnings Call Transcript
- Alkermes, Inc. F2Q09 (Qtr End 09/30/08) Earnings Call Transcript
- Akorn, Inc. Q3 2008 Earnings Call Transcript
- Energy XXI (Bermuda) Limited F1Q09 (Qtr End 09/30/08) Earnings Call Transcript
- The Advisory Board Company F2Q09 (Qtr End 09/30/08) Earnings Call Transcript
- Thomas Weisel Partners Group, Inc. Q3 2008 Earnings Call Transcript
- The9 Q3 2008 Earnings Call Transcript
-
Editors' Picks
-
Most Popular
- General Electric: Genuine Risk of Collapse?
- Food: Against Self-Sufficiency
- The Fed: Now the World's Largest Private Bank
- Key to the Global Equity Market: Trend and Cycle Analysis of U.S. Retail
- Can a Global Economy Be Managed One Nation at a Time?
- Global Markets Week in Review: Turbulent Times
- Full list of Editors' Picks »
- Jim Rogers on China »
- Memo to Warren: AmEx Preferred at 15%, Warrants at $12 »
- Should We Really Bail Out the Big Three Automakers with $73.20 Per Hour Labor? »
- Peak Oil's Bell Is Ringing »
- UltraShort ETFs: At a Tipping Point? »
- The Biggest Problem Detroit's Big Three Face »
- 11 Stocks Selling Below Cash »
- Tech May Be a Wreck, But This Isn't 2001 »
- The Autos and Mentality That Ruined Detroit »
- Iceland: What It's Like to Live in a World Without Money »
- Wall Street Breakfast: Must-Know News »
Hedge Fund Jobs
Job Seekers: Search jobs by category, get job alerts by email or live feed, apply online See full list of jobs »
Employers: See all recruitment options, get applications online or by email Post a job »
Dr_Dave
1 Comment
Elan, Biogen Idec Won't Gain Much from Tysabri Approval
You importantly failed to mention both cases of PML actually occurred in combo patients. The MS patient was receiving both Tysabri and Avonex, while the crohns patient was also prescribed with Remicade (a drug which actually causes PML). If you check the FDA site you will actually see that the remicade drug is listed as the primary suspect in this patient.
Tysabri has been much maligned due to ill-informed or partial representation of the true facts behind the drug. With almost 25,000 patients now receiving the drug and NO CASES OF PML, I certainly won't be surprised to see it continuing to confound analyst estimates.
By the way Elan has perhaps the most exciting drug candidate in the entire industry now in clinical trials! If that is successful you are talking a stock price which will be many multiples of todays! With an average success rate of around 70% for phase III trials, I think the risk:reward balance at these levels is amazingly good.